Marrone Bio Innovations Inc gets boosted $3.50 price target and repeat Buy rating from Bobby Burleson at Canaccord Genuity

Marrone Bio gets boosted $3.50 price target and repeat Buy rating from Canaccord Genuity
Analyst Bobby Burleson noted that the Marrone management team is speeding up the commercialization process and tightening its focus
Marrone Bio holds more than 400 issued and pending patents and has brought six US EPA-registered biological product lines and one biostimulant to market
Marrone Bio Innovations Inc (NASDAQ:MBII) (FRA:0MB) shares climbed Friday after an analyst at Canaccord Genuity upped the price target for the company to $3.50 from $2 and reiterated a Buy rating. 
The company introduced a 2022 revenue projection of $7.7 million based on “a continuing shift to seed and soil treatments and plant health solutions,” with an EBITDA of $1.2 million.   

Related Keywords

California ,United States ,Finland ,Finnish ,Canaccord Genuity ,Marrone Bio ,Bobby Burleson ,Kevin Helash , ,Pro Farm Technologies ,Pro Farm ,Protection Agency Registered ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,பின்லாந்து ,பின்னிஷ் ,கானக்கோர்ட் உண்மையானது ,மரோன் உயிர் ,பாபி பர்லேசன் ,ப்ரொ பண்ணை தொழில்நுட்பங்கள் ,ப்ரொ பண்ணை ,